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Amber Codon Flashing
Ambrx Augments Proteins
with Unnatural Amino AcidsProtein-based drugs, especially
those that have a natural source,
can be a recalcitrant lot. They may
trigger severe immune reactions in
patients or may survive only a short
time in the body, requiring patients
to take frequent injections to main-
tain consistent circulating drug
levels. Despite these drawbacks,
protein-based drugs such as insulin,
interferon, and human growth hor-
mone constitute a $40 billion market
that is expected to reach almost $59
billion by 2010. Given their impor-
tance and market potential, pharma-
ceutical companies are looking for
methods to optimize the therapeutic
properties of these proteins.
A commonly used method for opti-
mization isdirectmutagenesis,which
generates a sequence of random mu-
tations in the gene that encodes a
particular protein. The protein can
be either the drug itself or an enzyme
involved in the synthesis of the pro-
tein drug. The mutation will alter the
sequence of amino acids in the target
protein, potentially changing its func-
tionality. ‘‘Site-directed mutagenesis
is the backbone of modern biology,’’
but ‘‘we are still horrible at being
able to predict what will be the stabil-
ity of a protein,’’ says Thomas Mag-
liery, assistant professor of chemistry
at Ohio State.
Over the past two decades, chem-
ists have started incorporating ‘‘un-
natural’’ or synthetic amino acids
into proteins to optimize their func-
tionality and to enable scientists to
unravel complicated biochemical
processes in living organisms. ‘‘Un-
natural amino acids are in that phase
where they will be snowballing in the
next five years and everyone will be
using them for a variety of uses,’’
said Magliery.
‘‘In contrast to chemists’ ability to
manipulate small molecules, they
really can’t manipulate proteins, ex-
cept . by site-directed mutagene-
sis,’’ said Peter Schultz, professorof chemistry at The Scripps Re-
search Institute and director of the
Genomics Institute of the Novartis
Research Foundation (GNF). While
his group first used an in vitro ap-
proach to proteins, they experi-
enced difficulties in making the ami-
noacylated tRNAs and in producing
any reasonable amount of protein,
as it is a stoichiometric process. In
the late 80s, Schultz’s group spent
five years figuring out how to put
novel amino acid structures into
proteins by genetic engineering.
Ambrx uses its patented
technology platform,
called ReCode, to substi-
tute artificial amino acids
into proteins of bacteria
and yeast with efforts
in mammalian cells in
the works.
‘‘Probably the biggest tool will be
drug discovery.’’ Schultz said.
‘‘Roughly a third of INDs filed are
protein therapeutics. We’ve tradi-
tionally had small molecule thera-
peutics, and there is going to be an
increasing pipeline in biologics.
When chemists make small mole-
cule therapeutics, they spend a lot
of time optimizing the biological
properties, the stability, the chemi-
cal properties, the specificity, and
everything else. When people make
protein therapeutics, you are kind
of stuck with what nature gave you.’’
This method enables you ‘‘to
chemically modify proteins, but do
it genetically.’’ Schultz said. ‘‘So ev-
erything is absolutely pure, because
you are genetically encoding it. You
are making protein at the level of
the ribosome, and you have tremen-
dous translational fidelity.’’A Little Something Extra
San Diego-based Ambrx (www.
ambrx.com) and others take that
into practice in optimizing proteins
to meet the desired properties for
biologic drugs. Schultz cofounded
Ambrx in 2003 with Richard Di-
Marchi, former head of biologics at
Eli Lilly, where he was a codeveloper
of Humalog, an insulin analog, and
Troy Wilson. (Schultz is a serial
entrepreneur and has cofounded
other companies including Affymax
Research Institute, Syrrx, Kalypsys,
Phenomix, Symyx Therapeutics,
and Ilypsa.)
The privately held, 58 person
company has been capitalized by
three rounds of venture financing
and private placement comprising
about $90 million, says Martin
Mattingly, president and CEO. The
company’s series C financing in
2005 for $52 million led by Apposite,
included Glynn Ventures, the Dow
Employees’ Pension Plan, and
Union Carbide Employees’ Pension
Plan, as well as other venture funds.
Ambrx uses its patented technol-
ogy platform, called ReCode, to
substitute artificial amino acids into
proteins of bacteria and yeast, with
efforts in mammalian cells in the
works. The company is using their
platform to tailor proteins as drugs
and to optimize already existing pro-
tein-based drugs by reducing their
toxicity and/or increasing their half
life. ‘‘The goal of the process is to
incorporate into a biosynthetic pro-
tein, in our case therapeutic pro-
teins, chemistry that is not used by
natural organisms for the express
purpose of making better drugs.’’
says Thomas Daniel, M.D., chief sci-
entific officer.
Ambrx achieves this by using an
engineered tRNA so that the coding
sequence of the desired protein in-
corporates a synthetic amino acid
at an amber codon rather than let-
ting this codon signal for translation
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will not change the synthesis of the
protein in most cases. ‘‘That tRNA
has been modified so that it reads
the amber codon as a coding co-
don,’’ says Daniel. ‘‘It gives you tre-
mendous control because you put
the stop anywhere in the recombi-
nant DNA to direct the site on which
the amino acid is loaded.’’ The par-
ticular enzyme that attaches the
synthetic amino acid to the tRNA
that is associated with the amber
codon, the synthetase, is developed
by direct mutagenesis.
A Spoonful of Sugar Makes The
Medicine Go Down—and Last
Longer
The novel amino acid that Ambrx
adds to proteins enables the spe-
cific attachment of PEG (poly-
ethylene glycol) to the protein, a
process known in the industry as
PEGylation. PEGylating proteins
such as interferon, G-CSF, and
erythropoietin coats the offending
bits and helps the compounds to re-
side longer in the body. Drugs im-
proved by PEGylation include
Amgen’s Neulasta and Roche’s Pe-
ginterferon alfa-2a, called Pegasys.
However, with current technology,
it is impossible to reliably attach
PEG chains of consistent molecular
weight to proteins. Ambrx can use
ReCode to precisely control the
PEGs on each molecule. PEGylating
proteins is the company’s first appli-
cation, but it has also added anti-
bodies and small molecules to the
surface of proteins. The company
hopes to cut the cost of PEGylation
on an industrial scale as well.
ReCoding Proteins
Currently Ambrx is using ReCode to
optimize human growth hormone.
According to Mattingly, ‘‘we can
make scores of versions’’ of the
growth hormone as well as making
multiple changes to the protein in
multiple places, and by moving the
site of PEGylation by an amino acid,
‘‘we can get a substantial difference
in half life of the drug.’’ Ambrx is
expecting to initiate HGH clinical
trials in early 2007. The company is
also collaborating with Roche, an
investor in Ambrx, on a PEGylated
version of interferon a.
‘‘If you think of penicillin, a native
substance, today you have a second
and third generation, from the samecore,’’ said Mattingly. ‘‘Imagine the
future of protein drugs. If you start
with active drugs, the potential is
enormous.’’ A key hypothesis be-
hind Ambrx’s methodology is that
adding one synthetic amino acid to
a peptide or protein that is made of
hundreds if not thousands of amino
acids will not significantly alter the
3D structure of the protein. Working
within the existing pharmacopeia
will serve as a springboard for the
company to move on to developing
novel proteins as therapeutics.
Getting into the Unnaturals Biz
‘‘A lot of people are doing unnatu-
rals,’’ said Dennis Dougherty, pro-
fessor of chemistry at Cal Tech.
‘‘There is no doubt that Schultz is
the pioneer.’’ According to Dough-
erty, the first method that Schultz
developed in 1989 used chemistry
to put the amino acid on the tRNA.
Then, that reagent was used to in-
corporate the unnatural amino
acid. ‘‘Pretty much apart from Pete,
nobody in the world used that
method because you couldn’t
make very much protein,’’ said
Dougherty. ‘‘Because the RNA with
the amino acid attached was kind
of a difficult reagent to come by,
expensive and so on.’’ Now, other
groups are taking various ap-
proaches to protein design with
unnatural amino acids. Uttam Raj-
Bhandary, professor of molecular
biology at MIT, is trying to insert
two or more nonnatural amino acids
into proteins, mostly in eukaryotic
cells. Shigeyuki Yokoyama of the
University of Tokyo is also inserting
unnatural amino acids into proteins
in mammalian cells. According to
Dougherty, Sidney Hecht at the
University of Virginia developed the
fundamental methodology behind
the early Schultz work, but Hecht
did not at first incorporate unnatural
amino acids, although he is using
them now.
Dougherty also commented that
the more recent advances that
Ambrx utilizes, with which the labo-
ratory of David Tirrell, professor of
chemistry at Cal Tech, is also now
involved, use an enzymatic method
to charge the amino acid onto the
tRNA. The result is catalytic turn-
over, and the system becomes al-
most like normal protein expression,
enabling the expression of much
larger quantities of protein.Dougherty’s neuroscience labora-
tory at Cal Tech, in collaboration
with the biology laboratory of Henry
Lester, uses Schultz’s protocol to
study ion channels and neural re-
ceptors in vertebrate cells, which
requires only small quantities of
protein. Dougherty founded a small
company, Neurion, to do ion chan-
nel drug discovery. According to
Dougherty, sixty percent of the
targets of drug discovery are mem-
brane proteins, which are not readily
amenable to structural biology tech-
niques such as NMR or crystallogra-
phy. However, the unnatural amino
acid technique provides detailed
information on drug receptor inter-
actions.
Moving Beyond Proteins
David Tirrell is experimenting with
producing fluorinated amino acids
as probes. ‘‘The really pioneering
feature of Tirrell’s work is he was
certainly the first chemical engineer
to recognize that one could engineer
proteins in E. coli for materials prop-
erties and overexpress enough pro-
tein to make it reasonable for natural
amino acids and, subsequently,
with unnatural amino acids,’’ said
Dougherty. ‘‘The chemical strategy
is virtually limitless in terms of amino
acids you can use. The catalytic
system, if it becomes generally
available and in use, could be very
powerful. We will see if other labs
adopt it.’’
Ryan Mehl, a former postdoc in
Schultz’s laboratory, now an as-
sistant professor of chemistry at
Franklin and Marshall College, pub-
lished a paper in 2003 describing
an engineered E. coli that produces
a nonnatural amino acid and readily
incorporates it into proteins. Mehl
envisions sticky social implications.
It is ‘‘improving evolution with intelli-
gent design,’’ he quipped.
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